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IT has been known for many years that since Duchenne muscular dystrophy is in-
herited as an X-linked recessive trait only boys will manifest the disease and girls
in affected families will have a 50 per cent chance of being genetic carriers of the
condition. Although Duchenne dystrophy is a relatively uncommon condition with
possibly about 70 patients in Northern Ireland, the number of potential carriers is
much greater, since sisters, maternal aunts, and female cousins of the patient all
fall into this category. From incidence and prevalence figures (Nevin, 1975) it can
be calculated that, as a conservative estimate, there are about 500 potential carriers
in Northern Ireland, and the real figure may be much greater.
A considerable amount of effort has been put into the development of methods
of detecting carriers. All of the methods used are based on the "Lyon hypothesis"
(Lyon, 1961) that carriers suffer from a sub-clinical form of the disease. This hypo-
thesis has been criticised recently, but nevertheless it has formed a useful basis for
the investigation of the carrier state. Occasionally, clinical signs and symptoms of
the disease have been found in carriers and these findings include pseudo-hyper-
trophy and weakness (Chung, Morton, Peters, 1960; Emery, 1963). If then, the
carrier has a sub-clinical form of the disease, it follows that the methods which
have been used for carrier detection have been mainly those which are used
in diagnosing the fully expressed disease. Muscle morphology has been used at
light and electron microscopic levels, and abnormalities have been reported
(Pearson, Fowler and Wright, 1963; Gardner-Medwin, Pennington and Walton,
1971; Craig, Allen and MoCormick, in preparation). Electromyography has also
been used with some reported success (Gardner-Medwin, 1968). Several more
exotic methods such as muscle cell culture and muscle protein turnover rate have
been used but these methods have not been widely adopted largely due to the
technical problems involved.
It was with the development of diagnostic serum enzymology from 1950 onwards
that advances in carrier detection were made. The first positive results came in
1960 when Chung et al using aldolase and transaminase reported increased levels of
these enzymes in the cvrum of 15 per cent of mothers of boys with Duchenne mus-
cular dystrophy. Schapiro et al, also in 1960 reported increased levels of aldolase
and creatine phosphokinase (CPK) in 30 per cent of known carriers. Following pro-
gressive technical improvements in the method of serum CPK analysis, detection
rates steadily increased until detection rates of up to 75 per cent of known carriers
were possible (Walton and Gardner-Medwin 1969).
79In the present paper we would like to present our results for carrier detection in
Northern Ireland during the last few years, dealing exclusively with the results from
CPK analysis. Light microscopy, electron microscopy and electromyography are
also used, but because of the ease of obtaining the material (clotted blood) it has
been possible to investigate more carriers using CPK analysis than by the other
techniques.
MATERIALS AND METHODS
In our survey of serum CPK in carriers we have up to the present analysed
specimens from 125 potential carriers who were divided into three categories accord-
ing to the classification of Walton and Gardner-Medwin (1969):
Definite Carriers: Mothers of an affected son who have also an affected brother,
maternal uncle, sister's son or other male relative in the female line of inherit-
ance.
Probable Carriers: Mothers of two or more affected sons, who have no other
affected relatives.
Possible Carriers: Mothers of isolated cases and sisters and other female relatives
of affected males.
Five millilitres of clotted blood samples were taken from the subjects and serum
CPK was estimated, usually within two hours, using the Boehringer Test Combin-
ation 15790 (Boehringer, Mannheim, G.M.B.H.).
RESuLTS
in using CPK analysis to maximum advantage it is important that a well defined
normal range is determined and that one is aware of the many possible factors
which can interfere with serum CPK levels. Our normal range for females was
established using blood samples from 163 blood donors. The mean value was
found to be 16.3 mU/ml with a normal range of 1.7-37.5 mU/ml.
TABLE I
Per centof
No. of cases No. of cases with cases with
elevated CPK elevatedCPK
DEFINITE CARRIERS 12 11 91.7
PROBABLE CARRIERS 8 6 75.0
POSSIBLE CARRIERS 105 31 29.5
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The percentage of individuals with elevated CPK in each of the categories of
carrier is presented in Table I. From this it can be seen that elevated CPK was
found in all but one of the definite carriers. The one exception in this category wasfound to have normal levels of CPK on three separate occasions. In the group of
probable carriers 75 per cent of individuals had increased levels of CPK. Elevated
levels were found in about 30 per cent of potential carriers, this being a very
heterogeneous group consisting of aunts, cousins and sisters of dystrophy patients
and mother's of isolated cases.
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FIG. 1. Values for serum CPK in
potential carriers with elevated levels.
The normal range is represented by
the vertical bar.
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The scatter of CPK values in potential carriers with elevated levels is illustrated
in the figure. There is a wide range with values up to 15 times normal with a
marked cluster of results just above the upper limit of normal.
DISCUSSION
A consideration of the effectiveness of any method of carrier detection must
clearly be limited to the definite carriers since they are the only ones with known
genetic status. In the present investigation 11 of the 12 definite carriers had elevated
CPK indicating that CPK analysis is a very efficient indicator of the carrier state.
However, it is significant that one individual in this group had normal levels on
three occasions, raising the possibility that some carriers may be inherently unde-
tectable by the CPK method. This confirms the advisability of using more than one
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.method of carrier detection as it is suspected that normal CPK is not necessarily
accompanied by normal results in other carrier detection tests. Although CPK
estimation is in general the most sensitive test we have found two possible carriers
with normal CPK levels but marked abnormalities in muscle histology (Craig, Allen
and McCormick, 1975).
Since the "possible carrier" group is a heterogeneous one it is impossible to
estimate the number of carriers which it contains. It is obviously the group in which
carrier detection tests are very important since these subjects, at the time of
testing, have one or no dystrophic children and are of unknown genetic status. Our
results in the other categories suggest that most of the actual carriers within this
group will be detected by CPK analysis, but we again stress the desirability of
using as many criteria of carrier status as possible e.g. muscle histopathology,
electron microscopy, electromyography.
Although some carriers have grossly elevated levels of CPK there are many in
whom the increase is much less marked. For an accurate assessment of those results
it is necessary to have a precisely defined upper limit of normal, and subjects who
have values in the "borderline" range (just above or just below the limit) should
be tested on a number of occasions. Although multiple testing is most important
in this "borderline" group it should be done routinely in all subjects if possible
since occasional high values are found in normal individuals as a result of factors
such as unaccustomed muscular exercise and sub-clinical disease states (Griffiths,
1966; Graig and Smith, 1965). In particular, it should be noted that electromyo-
graphy and surgical procedures cause increased levels of CPK (Maeyens and Pitner,
1968; Phomphutkul et at, (1974). For this reason it is essential that on hospital
admission CPK estimation is performed before electromyography or muscle biopsy.
SUMMARY
Serum CPK estimation is a simple investigative procedure requiring only small
samples of blood and the present survey indicates that it produces a detection rate
of about 90 per cent for carriers of Duchenne muscular dystrophy. The importance
of a well defined normal range, multiple CPK analyses and an awareness of the
possibility of false positive results is stressed. In addition it is desirable when pos-
sible to use other methods for carrier detection such as muscle histopathology and
electromyography.
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